About Choice Therapeutics
Choice Therapeutics is a company based in Wrentham (United States) founded in 2006 was acquired by Alliqua in May 2014. Choice Therapeutics has raised $1.95 million across 2 funding rounds from investors including Alliqua. Choice Therapeutics operates in a competitive market with competitors including QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.
- Headquarter Wrentham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Choice Therapeutics
Choice Therapeutics has successfully raised a total of $1.95M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $582 thousand completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Choice Therapeutics
Choice Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Alliqua.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Wound care solutions through transdermal drug delivery
|
Locked | Locked | Locked |
Investor details for Choice Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Choice Therapeutics
Investment portfolio details for Choice Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Choice Therapeutics
Detailed financials for Choice Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Choice Therapeutics Comparisons
Peer comparison for Choice Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Choice Therapeutics
Choice Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as QBiotics, MediWound, Ilya Pharma, Resolution Therapeutics and ProFibrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| Locked | Locked | Locked |
Powdered fibrin sealant for surgical bleeding
|
|
| Locked | Locked | Locked |
Topical formulations for corneal wounds, ulcers, and scars are developed.
|
Detailed competitors of Choice Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Choice Therapeutics
Complete news archive for Choice Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Choice Therapeutics
Choice Therapeutics was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Choice Therapeutics is headquartered in Wrentham, United States. It is registered at Wrentham, Massachusetts, United States.
Jim Hutchens is the current CEO of Choice Therapeutics.
Choice Therapeutics is a funded company, having raised a total of $1.95M across 2 funding rounds to date.
Choice Therapeutics manufactures wound care products for burns, advanced wound care, and surgical site infections. It offers TheraBond 3D Contact Dressings used as contact layers for wounds; TheraBond 3D Wraps used as contact dressings configured in a bandage wrap design; and TheraBond 3D Island Dressings for incisions. TheraBond 3D provides infection prevention and protection in a variety of post-op scenarios such as Cardiothoracic surgery, Vascular surgery, Orthopedic surgery, Foot and ankle surgery and others. As of May 5, 2014, Choice Therapeutics operates as a subsidiary of Alliqua Biomedical.
Choice Therapeutics's top competitors include Ilya Pharma, QBiotics and Tempo Therapeutics.
Choice Therapeutics has 1 investor. Key investors include Alliqua.